Invivyd Prices Public Offering of Common Stock and Pre-Funded Warrants to Raise $50 Million

Invivyd Priced its Public Offering of Common Stock and Pre-funded Warrants in Millions

Announcement

Invivyd Inc. has revealed the pricing of an underwritten public offering of 74,811,404 shares of its common stock at a price of the offering by $0.52 per share for specific investors instead of common stock, and pre-funded warrants purchasing 21,342,442 shares of its common stock for $0.5199 per pre-funded warrant. The gross total proceeds with this offering price are predicted to be around an estimated $50.0 million before deduction of underwriting discounts and commissions, offering expenses payable by Invivyd. Each share purchase price of every pre-funded warrant shows the per share offering price for the common stock, minus the $0.0001 per share strike price of each similar pre-funded warrant.  

All pre-funded warrants and shares are provided by Invivyd. Additionally, the company has offered an alternative to the underwriter for 30 days, effective upon to purchase of up to an additional 14,423,076 shares of Invivyd common stock at the public offering price, with reduced underwriting commissions and discounts. The offering is predicted to close on or about 22nd August 2025, with title to the satisfaction of customary closing conditions. Cantor is a solo book-running manager for this offering.  

Invivyd’s Plans

Invivyd plans to utilize net proceeds receivable from the offering, together with its available cash equivalents and cash for trial protocol advancement, planning, and development of the VYD2311 clinical program. Also, research and development regarding the aligned programs like the advancement of the spike protein elimination, recovery (SPEAR) study group regarding the impact of monoclonal antibody therapy, and respiratory syncytial virus (RSV) and measles. Additionally, including the other general corporate purposes and working capital. These Invivyd securities are under a shelf registration statement on Form S-3.  

‘Offering’ in Detail

The offering is prepared using an accompanied prospectus and prospectus supplement, which is a part of the registration statement. A free writing prospectus and preliminary prospectus supplement regarding the offering filed with the SEC on 20th August 2025 are available on the SEC’s website at www.sec.gov. The final prospectus supplement regarding and explaining the terms of the offering will be filed with the SEC and will be available on the SEC’s official site. The copies of the final prospectus supplement on availability accompanying the prospectus based on the offering will be gained from Cantor Fitzgerald and Co., attention: equity capital markets, 110 East 59th Street, 6th floor, New York 10022, or via email at prospectus@cantor.com.